Seres

Seres Therapeutics’ oral microbiome treatment for C. difficile infections (CDI) proved superior to placebo in reducing CDI recurrence, according to Phase 3 data published last week in the New England Journal of Medicine. Touting the “first-ever positive pivotal clinical results for a targeted microbiome drug,” the Massachusetts-based company said in a press release it would finalize its U.S. FDA Biologics License Application for SER-109 in mid-2022.

The treatment boasts FDA…

Seres Therapeutics announced last week an agreement with Nestlé Health Science to jointly commercialize SER-109—the Massachusetts-based company’s investigational oral microbiome treatment for recurrent C. difficile infection—in the United States and Canada.

Under the deal, Seres will receive $175 million upfront in license payments, an additional $125 million upon U.S. FDA approval of the treatment, and up to $225 million in milestones. If approved, SER-109 would become the first U.S…

CARB-X announced yesterday that it is awarding German biotech Evotec up to $2.9 million (with a potential $5.5 million more in milestone payments) to develop a new class of broad-spectrum antibiotics to treat infections caused by multidrug-resistant Gram-positive and Gram-negative bacteria.

In other antibiotics news this week, Massachusetts-based Seres Therapeutics announced positive topline results from a Phase 3 trial of its oral microbe-based treatment for recurrent C. difficile…